disruptpress efi

Pfizer plans to file for full FDA approval of Covid vaccine at the end of this month

In this article

A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020.
Dado Ruvic | Reuters

Pfizer said Tuesday it plans to file for full U.S. approval of its Covid-19 vaccine with German drugmaker BioNTech at the end of this month. If the FDA signs off, the company will be able to market the shot directly to consumers.

In releasing its first-quarter financial results, the company also reported $3.5 billion in first-quarter sales of its Covid-19 and reported earnings and revenue that beat Wall Street’s expectations.

Here’s how Pfizer did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: 93 cents per share vs 77 cents expected
  • Revenue: $14.58 billion vs. $13.51 billion expected

The company now expects full-year sales of $26 billion from the vaccine, up from its previous forecast of about $15 billion.

Shares of Pfizer rose 1.4% after the news.

This is a developing story. Please check back for updates.

Products You May Like

Articles You May Like

Home Depot crushes estimates, its sales jump 32.7% as customers rang up bigger purchases
Dr. Anthony Fauci’s advice to Vanderbilt grads: Never stop learning and ‘cultivate joy,’ not just professional accomplishments
Stock futures are flat after Wall Street begins week with modest losses
Small business owners missed out on thousands of dollars in loans when PPP funding ran out early
What To Do When You Notice Your Aging Parents Are Starting To “Slip”

Leave a Reply

Your email address will not be published. Required fields are marked *